Oppenheimer initiated coverage of SAB Biotherapeutics (SABS) with an Outperform rating and $12 price target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SABS:
- SAB BIO Announces Second Quarter 2024 Financial Results and Provides Company Updates
- SAB Biotherapeutics founds Clinical Advisory Board for SAB-142 development
- SAB BIO Announces Founding of Clinical Advisory Board to Guide the Development of SAB-142 for Type 1 Diabetes
- SAB Biotherapeutics Announces Key Executive Appointment
- SAB BIO Appoints Lucy To as Chief Financial Officer